Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002656
Status:
COMPLETED
Last Update Posted:
2013-04-29
First Post:
1999-11-01
Brief Title:
Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer
Sponsor:
Barbara Ann Karmanos Cancer Institute
Organization:
Barbara Ann Karmanos Cancer Institute
Study Overview
Official Title:
PHASE II CLINICAL EVALUATION OF PYRAZOLOACRIDINE IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CARCINOMA
Status:
COMPLETED
Status Verified Date:
2013-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE Phase II trial to study the effectiveness of chemotherapy with pyrazoloacridine in treating patients with stage IIIB or stage IV non-small cell lung cancer
PURPOSE Phase II trial to study the effectiveness of chemotherapy with pyrazoloacridine in treating patients with stage IIIB or stage IV non-small cell lung cancer
Detailed Description:
OBJECTIVES I Evaluate the antitumor activity of pyrazoloacridine PZA administered by 3-hour infusion to patients with advanced non small cell lung cancer NSCLC II Determine the qualitative and quantitative toxicities of PZA administered on this schedule III Determine the response and survival durations of NSCLC patients treated with PZA
OUTLINE Single-Agent Chemotherapy Pyrazoloacridine PZA NSC-366140
PROJECTED ACCRUAL If 2 or 3 responses are observed in the first 18 evaluable patients 12 additional patients will be entered Accrual is expected to take 5-12 months
OUTLINE Single-Agent Chemotherapy Pyrazoloacridine PZA NSC-366140
PROJECTED ACCRUAL If 2 or 3 responses are observed in the first 18 evaluable patients 12 additional patients will be entered Accrual is expected to take 5-12 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-T94-0001H | US NIH GrantContract | None | httpsreporternihgovquickSearchP30CA022453 |
| P30CA022453 | NIH | None | None |
| WSU-C-1087-93 | None | None | None |